EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Overcoming Liquid Biopsy Barriers: Nucleic Acid Biosensors Integrating DNA Nanotechnology and CRISPR−Cas System for Cancer Precision Theranostics

Yutong Lv, Kulsoom, Lijun Jia, Zhenlong Wang, Fu Wang iD

ACS Sensors · 2026

DOI: 10.1021/acssensors.6c01673 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Sensors, 2026. Verfasst von Yutong Lv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an710004, China. Hauptthemen laut MEDLINE: Biosensing Techniques, Neoplasms, CRISPR-Cas Systems, Theranostic Nanomedicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Xi'an Municipal Bureau of Science and Technology, Natural Science Basic Research Program of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy holds immense potential for the early detection of cancer, yet its clinical utility is hindered not by the lack of available tumor-associated biomarkers but by the inadequate sensitivity and clinical robustness of current molecular diagnostic tools. Nucleic acid-based biosensors have emerged as highly programmable platforms, enabling the detection of low-abundance cancer biomarkers such as microRNAs (miRNAs), circulating tumor DNA (ctDNA), and messenger RNAs (mRNAs) in complex biological fluids. Leveraging advances in DNA nanotechnology, CRISPR−Cas-mediated RNA sensing, and chemically engineered nucleic acid analogues, these biosensors achieve attomolar-level detection through nanoscale spatial confinement and enzyme-assisted signal amplification strategies. However, their clinical translation is hindered by biological sample variability, nonspecific amplification, probe degradation, and poor reproducibility. This review analyzes the core design principles of three major biosensor categories: functional DNA nanostructures, CRISPR−Cas-based sensing systems, and synthetic analogues (PNAs, SNAs). It elucidates their structural and enzymatic optimization mechanisms, distinguishes analytical from clinical sensitivity, and addresses key liquid biopsy challenges. Finally, it outlines promising strategies for clinical translation, including microfluidic integration, artificial intelligence-assisted data analysis, and theranostic nanostructures combining diagnosis with targeted therapy. This review provides a comprehensive theoretical and technical framework for the rational design of next-generation nucleic acid biosensors and offers critical insights to bridge the gap between nanoscale engineering innovation and clinical translation, ultimately advancing the development of minimally invasive and precise cancer theranostics in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosensing TechniquesNeoplasmsCRISPR-Cas SystemsTheranostic NanomedicineNanotechnologyHumansLiquid BiopsyDNA NanostructuresPrecision MedicineBiomarkers, Tumor

Stichwörter der Autor:innen

CRISPR−CasDNA nanotechnologyartificial intelligencecancer theranosticsliquid biopsynucleic acid biosensorpeptide nucleic acidsspherical nucleic acids

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an710004, China.
  • Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an710061, China.
  • Department of Medical Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an710004, China.
  • Xianyang Key Laboratory of Molecular Imaging and Drug Synthesis, School of Pharmacy, Shaanxi Institute of International Trade & Commerce, Xianyang712046, China.

ORCID-Profile: Fu Wang

Förderung

  • National Natural Science Foundation of China
  • Xi'an Municipal Bureau of Science and Technology
  • Natural Science Basic Research Program of Shaanxi Province

Zitieren

APA

Lv, Y., Kulsoom, Jia, L., Wang, Z., & Wang, F. (2026). Overcoming Liquid Biopsy Barriers: Nucleic Acid Biosensors Integrating DNA Nanotechnology and CRISPR−Cas System for Cancer Precision Theranostics. ACS Sensors. https://doi.org/10.1021/acssensors.6c01673

Vancouver

Lv Y, Kulsoom, Jia L, Wang Z, Wang F. Overcoming Liquid Biopsy Barriers: Nucleic Acid Biosensors Integrating DNA Nanotechnology and CRISPR−Cas System for Cancer Precision Theranostics. ACS Sensors. 2026. doi:10.1021/acssensors.6c01673

BibTeX
@article{Lv2026,
  author = {Lv, Yutong and Kulsoom and Jia, Lijun and Wang, Zhenlong and Wang, Fu},
  title = {Overcoming Liquid Biopsy Barriers: Nucleic Acid Biosensors Integrating DNA Nanotechnology and CRISPR−Cas System for Cancer Precision Theranostics},
  journal = {ACS Sensors},
  year = {2026},
  doi = {10.1021/acssensors.6c01673}
}
Kostenlos starten →